Stocks and Investing Stocks and Investing
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022
Thu, February 24, 2022

Douglas Tsao Maintained (TBPH) at Strong Buy with Increased Target to $12 on, Feb 24th, 2022


Published on 2024-10-27 19:48:58 - WOPRAI, Douglas Tsao
  Print publication without navigation


Douglas Tsao of HC Wainwright & Co., Maintained "Theravance Biopharma, Inc." (TBPH) at Strong Buy with Increased Target from $8 to $12 on, Feb 24th, 2022.

Douglas has made no other calls on TBPH in the last 4 months.



There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, all agrees with Douglas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Increased Target to $12 on, Friday, November 5th, 2021